依达拉奉联合醒脑静对颅脑外伤后脑血管痉挛患者的临床疗效观察

目的: 探讨分析依达拉奉联合醒脑静对颅脑外伤后脑血管痉挛患者的治疗效果.方法: 以2014年11月-2016年11月本院收治的颅脑外伤后脑血管痉挛60例患者为研究对象,按照随机数表法分为对照组和观察组,各30例,对照组患者采用常规治疗的基础上给予依达拉奉30 mg,用氯化钠注射液稀释后静脉滴注,2次/d,10 d为1个疗程.观察组在对照组基础上加用醒脑静注射液10 ml加入250 ml葡萄糖注射液中静脉滴注,1次/d,10 d为1个疗程.结果:两组患者在入院后第1日的大脑前动脉、中动脉和后动脉、以及椎动脉和基底动脉的血流速度比较无显著性差异;入院两周后,观察组患者各个部位的血流速度明显低于对照组患者;入院第1日,两组患者的格拉斯哥昏迷评分比较差异无显著性;入院后的第7日和第14日比较差异有显著性;对照组脑梗死发生率为16.7％,观察组脑梗死发生率为3.3％,两组比较差异有显著性. 结论:依达拉奉联合醒脑静能够明显改善颅脑外伤后脑血管痉挛患者的症状,值得临床推广应用.

Clinical observation of edaravone combined with xingnaojing in patients with cerebral vasospasm after craniocerebral trauma

Objective: To investigate the effect of edaravone combined with Xingnaojing on cerebral vasospasm after craniocerebral trauma.Methods: Sixty patients with cerebral vasospasm after craniocerebral trauma in our hospital from November 2014 to November 2016 were randomly divided into the control group and the observation group according to the random number table.Edaravone was given to the thirty patients in the control group, while Xingnaojing and edaravone was co-administered to the patients in the observation group.Therapeutic effect of the two groups was observed.Results: There were no significant differences in the blood flow velocity between the anterior, middle and posterior arteries, and between the vertebral and basilar arteries on the first day after admission.After two weeks of hospitalization, the blood flow in the above mentioned areas in the patients of the observation group was improved more significantly than in the observation group.The rate of glaucoma coma in the observation group was significantly lower than that in the control group, even though no significant difference in Glasgow coma score was found between the two groups on the first day of hospitalization.The incidence of cerebral infarction in the control group and in the observation group was 16.7％ and 3.3％,respectively, there existing a significant difference.Conclusion:Edaravone combined with Xingnaojing can significantly improve the symptoms of patients with cerebral vasospasm after craniocerebral trauma, and it is worthy of clinical application.